Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas

Blood

Volumn 113, Issue 11, 2009, Pages 2478-2487

  Frank, Matthew J ^a   Dawson, David W ^a,b   Bensinger, Steven J ^a,c   Hong, Jason S ^a   Knosp, Wendy M ^d   Xu, Lizhong ^e   Balatoni, Cynthia E ^a   Allen, Eric L ^a   Shen, Rhine R ^a   Bar Sagi, Dafna ^e   Martin, Gail R ^d   Teitell, Michael A ^a,b,c  

^a Department of Pathology and Laboratory Medicine ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; DNA; MITOGEN ACTIVATED PROTEIN KINASE; SPROUTY PROTEIN; SPROUTY2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA METHYLATION; DNA SYNTHESIS INHIBITION; EPIGENETICS; FEEDBACK SYSTEM; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

EID: 63849272814     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-156943     Document Type: Article

References (59)

1. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291- 3310.
2. Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/ mTOR and Jak/STAT pathways to leukemia. Leukemia. 2008;22:686-707.
3. Kim HJ, Bar-Sagi D. Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol. 2004;5:441-450.
4. Said JW, Hoyer KK, French SW, et al. TCL1 on- cogene expression in B cell subsets from lym- phoid hyperplasia and distinct classes of B cell lymphoma. Lab Invest. 2001;81:555-564.
5. Teitell M, Damore MA, Sulur GG, et al. TCL1 on- cogene expression in AIDS-related lymphomas and lymphoid tissues. Proc Natl Acad Sci U S A. 1999;96:9809-9814.
6. Teitell MA. TheTCL1 family of oncoproteins: co- activators of transformation. Nat Rev Cancer. 2005;5:640-648.
7. Hoyer KK, French SW, Turner DE, et al. Dysregu- lated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA. 2002;99:14392-14397.
8. Hoyer KK, Herling M, Bagrintseva K, et al. Tcell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol. 2005;175:864-873.
9. Suzuki A, Kaisho T, Ohishi M, et al. Critical roles of Pten in B cell homeostasis and immunoglobu- lin class switch recombination. J Exp Med. 2003; 197:657-667.
10. Shen RR, Ferguson DO, Renard M, et al. Dys- regulated TCL1 requires the germinal center and genome instability for mature B-cell transformation. Blood. 2006;108:1991-1998.
11. Teitell MA, Lones MA, Perkins SL, Sanger WG, Cairo MS, Said JW. TCL1 expression and Ep- stein-Barr virus status in pediatric Burkitt lym-phoma. Am J Clin Pathol. 2005;124:569-575.
12. Dawson DW, Hong JS, Shen RR, et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene. 2007; 26:4243-4252.
13. Costello JF, Smiraglia DJ, Plass C. Restriction landmark genome scanning. Methods. 2002;27: 144-149.
14. CostelloJF, Fruhwald MC, SmiragliaDJ,et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000;24:132-138.
15. Esteller M. Cancer epigenetics: DNAmethylation and chromatin alterations in human cancer. Adv Exp Med Biol. 2003;532:39-49.
16. French SW, Dawson DW, Miner MD, et al. DNA methylation profiling: a new tool for evaluating hematologic malignancies. Clin Immunol. 2002; 103:217-230.
17. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
18. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell. 1998;92:253-263.
19. Christofori G. Split personalities: the agonistic antagonist Sprouty. Nat Cell Biol. 2003;5:377-379.
20. Mason JM, Morrison DJ, Basson MA, Licht JD. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol. 2006;16:45-54.
21. Cabrita MA, Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis. 2008;11:53-62.
22. Choi H, Cho SY, Schwartz RH, Choi K. Dual effects of Sprouty1 on TCR signaling depending on the differentiation state of the Tcell. J Immunol. 2006;176:6034-6045.
23. Hall AB, JuraN, DaSilva J, Jang YJ, Gong D, Bar-Sagi D. hSpry2 is targeted to the ubiquitin- dependent proteasome pathway by c-Cbl. Curr Biol. 2003;13:308-314.
24. Rubin C, Litvak V, Medvedovsky H, Zwang Y, Lev S, Yarden Y. Sprouty fine-tunes EGF signaling through interlinked positive and negative feed back loops. Curr Biol. 2003;13:297-307.
25. Wong ES, Guy GR. Regulator of epidermal growth factor signaling: Sprouty. Methods Mol Biol. 2006;327:61-83.
26. Lo TL, Fong CW, Yusoff P, et al. Sprouty and cancer: the first terms report. Cancer Lett. 2006;242: 141-150.
27. McKie AB, Douglas DA, Olijslagers S, et al. Epi- genetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene. 2005;24:2166-2174.
28. Fritzsche S, Kenzelmann M, Hoffmann MJ, et al. Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer. 2006;13:839-849.
29. Sutterluty H, Mayer CE, Setinek U, et al. Down- regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res. 2007;5:509-520.
30. Fong CW, Chua MS, McKie AB, et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res. 2006;66:2048-2058.
31. Lo TL, Yusoff P, Fong CW, et al. The ras/mitogen- activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res. 2004;64:6127-6136.
32. Courtois-Cox S, Genther Williams SM, Reczek EE, et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell. 2006;10:459-472.
33. Lito P, Mets BD, Kleff S, O'Reilly S, Maher VM, McCormick JJ. Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene- transformed human fibroblasts. J Biol Chem. 2008;283:2002-2009.
34. Sanchez A, Setien F, Martinez N, et al. Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas. Oncogene. 2008;27:4969- 4972.
35. Shim K, Minowada G, Coling DE, Martin GR. Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Dev Cell. 2005;8: 553-564.
36. Morse HC 3rd, Anver MR, Fredrickson TN, et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 2002;100:246-258.
37. Omori SA, Wall R. Multiple motifs regulate the B-cell-specific promoter of the B29 gene. Proc Natl Acad Sci USA. 1993;90:11723-11727.
38. Kuraishy AI, French SW, Sherman M, et al. TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation. Proc Natl Acad Sci USA. 2007;104:10175-10180.
39. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007;129:1065-1079.
40. Rush LJ, Raval A, Funchain P, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 2004;64: 2424-2433.
41. Ding W, Bellusci S, Shi W, Warburton D. Functional analysis of the human Sprouty2 gene promoter. Gene. 2003;322:175-185.
42. Wheeler K, Gordon J. Co-ligation of surface IgM and CD40 on naive B lymphocytes generates a blast population with an ambiguous extrafollicu- lar/germinal centre cell phenotype. Int Immunol. 1996;8:815-828.
43. Mizuno T, Rothstein TL. B cell receptor (BCR) cross-talk: CD40 engagement enhances BCR- induced ERK activation. J Immunol. 2005;174: 3369-3376.
44. Ozaki K, Kadomoto R, Asato K, TanimuraS, Itoh N, Kohno M. ERK pathway positively regulates the expression of Sprouty genes. Biochem Bio- phys Res Commun. 2001;285:1084-1088.
45. Coughlin JJ, Stang SL, Dower NA, Stone JC. RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J Immunol. 2005;175:7179-7184.
46. Brunet A, Pages G, Pouyssegur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene. 1994; 9:3379-3387.
47. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med. 2005;202:1363-1374.
48. Daniel J, Marechal Y, Van Gool F, Andris F, Leo O. Nicotinamide inhibits B lymphocyte activation by disrupting MAPK signal transduction. Biochem Pharmacol. 2007;73:831-842.
49. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
50. Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci U S A. 1988;85:9268-9272.
51. Lee JW, Yoo NJ, Soung YH, et al. BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer. 2003;89:1958-1960.
52. Stiller CA, Chessells JM, Fitchett M. Neurofibro- matosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer. 1994;70:969-972.
53. Impagnatiello MA, Weitzer S, Gannon G, Compagni A, Cotten M, Christofori G. Mammalian sprouty-1 and -2 are membrane-anchored phos- phoprotein inhibitors of growth factor signaling in endothelial cells. J Cell Biol. 2001;152:1087-1098.
54. Shaw AT, Meissner A, Dowdle JA, et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev. 2007;21:694-707.
55. Land H, Chen AC, Morgenstern JP, Parada LF, Weinberg RA. Behavior of myc and ras onco- genes in transformation of rat embryo fibroblasts. Mol Cell Biol. 1986;6:1917-1925.
56. Alexander WS, Adams JM, Cory S. Oncogene cooperation in lymphocyte transformation: malignant conversion of E mu-myc transgenic pre- B cells in vitro is enhanced by v-H-ras or v-raf but not v-abl. Mol Cell Biol. 1989;9:67-73.
57. Richards JD, Dave SH, Chou CH, Mamchak AA, DeFranco AL. Inhibition of the MEK/ERK signaling pathway blocks a subset of B cell responses to antigen. J Immunol. 2001;166:3855-3864.
58. Takahashi Y, Inamine A, Hashimoto S, et al. Novel role of the Ras cascade in memory B cell response. Immunity. 2005;23:127-138.
59. Rui L, Healy JI, Blasioli J, Goodnow CC. ERK signaling is a molecular switch integrating opposing inputs from B cell receptor and T cell cyto- kines to control TLR4-driven plasma cell differentiation. J Immunol. 2006;177:5337-5346.